MBBS, MRCP (UK), M Med (Internal Medicine), FAMS
Specialty: Medical Oncology
Sub-specialties: Breast, Gynae-Oncology
Conditions Treated by this Doctor:
Breast Cancer , Gynaecological Cancers.
Dr Jack Chan is a Consultant in the Division of Medical Oncology at National Cancer Centre Singapore, and a Visiting Consultant with Department of Gynaecological Oncology at KK Women’s and Children’s Hospital. Dr Chan completed his specialist training in Medical Oncology at NCCS, and is a Fellow of the Academy of Medicine, Singapore. He did his advanced fellowship in early drug development and translational medicine in gynaecological cancers at Cancer Research UK Edinburgh Centre and Edinburgh Cancer Centre under the Health Manpower Development Plan Award.
Dr Chan’s subspecialty interests are gynaecological cancers and breast cancer. His research interests include early and late phase clinical trials and translational work in gynaecological and breast cancers. He is the Principal Investigator of investigator-initiated and industry-sponsored trials at NCCS. Dr Chan is also active in teaching Senior Residents, medical officers, medical and nursing students; as well as in professional societies such as the Gynecological Cancer Group Singapore and College of Physicians, Academy of Medicine, Singapore. He has received accolades for his education and clinical work, including Residency in SingHealth Excels Outstanding Faculty Award 2020 and Singapore Health Quality Service Awards (Silver 2019, Gold 2020).
Dr Chan believes in taking a personalised approach to cancer care. He strives to support his patients and their families through navigating the cancer journey by addressing both their medical needs and quality of life.
Dean’s List, Yong Loo Lin School of Medicine, National University of Singapore, 2004, 2005, 2007
Ng DQ, Tan CJ, Soh BC, Tan MML, Loh S, Tan YE, Ong HH, Teng PPC, Chan JJ, Chay WY, Lee J, Lai GGY, Beh SY, Tan T, Yap YS, Lee GE, Wong M, Dent R, Lo Y, Chan A, Loh KW. Impact of cryotherapy on sensory, motor, and autonomic neuropathy in breast cancer patients receiving paclitaxel: a randomized, controlled trial. Front Neurol 2020; 11:604688.
Chan JJ, Tan TJY, Dent RA. Integrating immunotherapy in the (neo)adjuvant setting of early breast cancer. Curr Opin Oncol 2020; 32(6):575-84.
Chan JJ, Sim Y, Ow SGW, Lim JSJ, Kusumawidjaja G, Zhuang Q, Wong RX, Wong FY, Tan VKM, Tan TJY. The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience. Endocr Relat Cancer 2020; 27(9):R307-27.
Chan JJ, Tan TJY, Dent RA. Novel therapeutic avenues in triple negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond. Ther Adv Med Oncol 2019; 11:1758835919880429.
Tan CJ, Lim SWT, Toh YL, Ng T, Yeo A, Shwe M, Foo KM, Chu P, Jain A, Koo SL, Dent RA, Ng RCH, Yap YS, Lim EH, Loh KW, Chay WY, Lee GE, Tan TJY, Beh SY, Wong M, Chan JJ, Khor CC, Ho HK, Chan A. Replication and meta-analysis of the association between BDNF Val66Met polymorphism and cognitive impairment in patients receiving chemotherapy. Mol Neurobiol 2019; 56(7):4741-50.
Chan JJ, Tan TJY, Dent RA. Are there any clinically relevant subgroups of triple-negative breast cancer in 2018? J Oncol Pract 2018; 14(5): 281-9.
Tan TJ, Chan JJ, Kamis S, Dent R. What is the role of immunotherapy in breast cancer. Chin Clin Oncol 2018; 7(2): 13.
Lee JXJ, Chan JJ, Choo SP. Clinical development of c-MET inhibition in hepatocellular carcinoma. Diseases 2015; 3(4): 306-24.
Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-02) (ClinicalTrials.gov Identifier: NCT04620954) (Principal Investigator)
Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin (ORION-01) (ClinicalTrials.gov Identifier: NCT03100006) (Principal Investigator)
Subscribe to our mailing list to get the updates to your inbox